Skip to main content

Table 6 Number of TAND studies according to country (and study type)

From: The research landscape of tuberous sclerosis complex–associated neuropsychiatric disorders (TAND)—a comprehensive scoping review

Countries

Total (A, CS, CO)

Countries

Total (A, CS, CO)

Countries

Total (A, CS, CO)

Countries

Total (A, CS, CO)

Countries (S-U)

Total (A, CS, CO)

Argentina

1 (0, 0, 1)

Denmark

4 (0, 0, 4)

Israel

3 (0, 0, 3)

Norway

4 (0, 0, 4)

South Africa

5 (0, 0, 5)

Australia

9 (2, 0, 7)

Egypt

1 (0, 0, 1)

Italy

18 (1, 1, 16)

Oman

2 (0, 2, 0)

South Korea

8 (0, 2, 6)

Austria

4 (0, 0, 4)

Estonia

3 (0, 0, 3)

Japan

10 (1, 3, 6)

Pakistan

1 (0, 1, 0)

Spain

6 (0, 0, 6)

Belgium

6 (0, 0, 6)

France

9 (0, 2, 7)

Latvia

3 (0, 0, 3)

Poland

10 (0, 1, 9)

Sweden

5 (0, 0, 5)

Canada

7 (2, 0, 5)

Germany

14 (6, 0, 8)

Lithuania

3 (0, 0, 3)

Portugal

4 (0, 0, 4)

Taiwan

6 (0, 0, 6)

China

10 (0, 1, 9)

Greece

4 (0, 0, 4)

Malaysia

1 (0, 0, 1)

Romania

3 (0, 0, 3)

Thailand

4 (0, 0, 4)

Colombia

1 (0, 0, 1)

Hungary

1 (0, 0, 1)

Mexico

1 (0, 0, 1)

Russia

4 (0, 0, 4)

Turkey

4 (0, 0, 4)

Croatia

1 (0, 1, 0)

India

9 (0, 9, 0)

Netherlands

14 (0, 1, 13)

Slovakia

3 (0, 0, 3)

UK

50 (0, 5, 45)

Czech Republic

5 (0, 0, 5)

Ireland

1 (0, 0, 1)

New Zealand

1 (0, 1, 0)

Slovenia

3 (0, 0, 3)

USA

89 (21, 12, 56)

  1. Countries listed in alphabetical order. A animal studies, CS case studies, CO cohort studies. Three hundred forty-one individual research sites across 230 studies depicted according to country, as multisite large-scale registry studies are also represented (e.g. Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy—Tuberous Sclerosis Complex (EPISTOP) and TuberOus SClerosis registry to increase disease Awareness (TOSCA)). Please note that specific European countries described in one study as ‘other European countries’ are not represented [90]